A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors (NCT06619587)
A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
Who can join: Review the eligibility criteria below.
Location: UC San Diego Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (42 Sites)
Showing the first 25 of 42 sites.
- UC San Diego Moores Cancer Center — La Jolla, California
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Florida Cancer Specialist-Lake Mary — Lake Mary, Florida
- University of Illinois — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- START - Midwest - EDOS — Grand Rapids, Michigan
- Montefiore Einstein Cancer Center — The Bronx, New York
- Mary Crowley Medical Research Center — Dallas, Pennsylvania
- Abramson Cancer Center;Univ of Pennsylvania — Philadelphia, Pennsylvania
- SCRI Oncology Partners — Nashville, Tennessee
- O'Quinn Medical Tower at McNair Campus — Houston, Texas
- St Vincent's Hospital Sydney — Darlinghurst, New South Wales
- Slade Health Inward goods — Mount Kuring-Gai, New South Wales
- Peter Maccallum Cancer Centre — Parkville, Victoria
- British Columbia Cancer Agency — Vancouver, British Columbia
- Princess Margaret Cancer Centre — Toronto, Ontario
- Sir Mortimer B Davis Jewish General Hospital — Montreal, Quebec
- Gustave Roussy — Villejuif, Val-de-Marne
- Institut Bergonie — Bordeaux,
- Centre Georges Francois Leclerc — Dijon,
- Rambam Health Care Campus — Haifa,
- Hadassah University Hospital - Ein Kerem — Jerusalem,
- The Chaim Sheba Medical Center — Ramat Gan,
- Tel Aviv Sourasky Medical Center PPDS — Tel Aviv,
📞 Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.